相关实验视频
Updated: May 23, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
通过SEI1通过化疗介导的PD-L1诱导促进骨髓瘤免疫逃避
Rui Chen1, Zongwei Li2, Zhihong Fang3,4
1Cancer Research Center, School of Medicine, Xiamen University, Xiamen, 361102, China.
多发性骨髓瘤的化疗激活了cGAS/STING通路,增加了PD-L1和免疫逃逸. 结合化疗和PD-L1阻断后治疗,可以增强T细胞的杀死,改善骨髓瘤治疗.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 多发性骨髓瘤 (MM) 是一种血细胞恶性瘤,化学疗法是标准的,但其与免疫疗法的相互作用尚不清楚.
- 免疫检查点封锁已经推进了MM治疗,但化疗在调节免疫反应中的作用需要阐明.
研究的目的:
- 为了研究化疗如何影响多发性骨髓瘤的免疫检查点表达.
- 揭示化学疗法与免疫逃避有关的分子机制,并确定治疗策略.
主要方法:
- 多发性骨髓瘤的体外和体外模型.
- 循环氨酸单酸 (GMP) - 氨酸单酸 (AMP) 合成酶 (cGAS) /干扰素基因刺激器 (STING) 信号通路的分析.
- 评估编程死亡-1 (PD-L1) 表达和T细胞介导的细胞毒性.
主要成果:
- 化疗药物诱导DNA损伤,激活cGAS/STING通路.
- 这种激活通过IRF7和SEI1升调编程死亡干-1 (PD-L1),促进免疫逃逸.
- 用PD-L1抗体进行化疗后的治疗显著增强了T细胞杀死髓瘤细胞.
结论:
- 化疗通过cGAS/STING-IRF7-SEI1轴调节PD-L1,有助于在多发性骨髓瘤中免疫逃逸.
- 结合化疗和PD-L1阻断的序列治疗为增强多发性骨髓瘤治疗提供了一个有前途的战略.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
相关概念视频
Tumor Immunotherapy
Abnormal Proliferation
The Tumor Microenvironment
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...